Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease

Kidney International

Volumn 80, Issue 5, 2011, Pages 453-463

  Swaminathan, Sundararaman ^a   Shah, Sudhir V ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Acute kidney injury; Cardiovascular disease; Chronic kidney disease; Inflammation

Indexed keywords

CALCIPROTEIN; CHOLESTEROL; GLYCOPROTEIN; HEME; HIGH DENSITY LIPOPROTEIN; IRON; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; INNATE IMMUNITY; IRON METABOLISM; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOCYTE FUNCTION; LIPOPROTEIN BLOOD LEVEL; MONOCYTE; NEPHROSCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; ATHEROSCLEROSIS; KIDNEY DISEASE; PATHOLOGY;

ATHEROSCLEROSIS; HUMANS; INFLAMMATION; KIDNEY DISEASES; RISK FACTORS;

EID: 84857086983     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.178     Document Type: Short Survey

References (167)

1. Lindner A, Charra B, Sherrard DJ et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
3. Foley RN, Murray AM, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495. (Pubitemid 41725146)
4. Collins AJ, Li S, Gilbertson DT et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 2003; 64: S24-S31. (Pubitemid 37315504)
5. Ross R, Harker L. Hyperlipidemia and atherosclerosis. Science 1976; 193: 1094-1100.
6. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010; 10: 826-837.
7. Libby P, Okamoto Y, Rocha VZ et al. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010; 74: 213-220.
8. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010; 7: 77-86.
9. Poole JC, Florey HW. Changes in the endothelium of the aorta and the behaviour of macrophages in experimental atheroma of rabbits. J Pathol Bacteriol 1958; 75: 245-251.
10. Suzuki M, O'Neal RM. Circulating lipophages, serum lipids, and atherosclerosis in rats. Arch Pathol 1967; 83: 169-174.
11. Wurster NB, Zilversmit DB. The role of phagocytosis in the development of atherosclerotic lesions in the rabbit. Atherosclerosis 1971; 14: 309-322.
12. Geer JC. Fine structure of human aortic intimal thickening and fatty streaks. Lab Invest 1965; 14: 1764-1783.
13. Ross R. The Gordon Wilson Lecture: atherosclerosis-a response to injury gone awry. Trans Am Clin Climatol Assoc 1982; 93: 78-86.
14. Greenberg CS, Hammerschmidt DE, Craddock PR et al. Atheroma cholesterol activates complement and aggregates granulocytes: possible role in ischemic manifestations of atherosclerosis. Trans Assoc Am Physicians 1979; 92: 130-135. (Pubitemid 10124914)
15. Joris I, Stetz E, Majno G. Lymphocytes and monocytes in the aortic intima-an electron-microscopic study in the rat. Atherosclerosis 1979; 34: 221-231. (Pubitemid 10209101)
16. Schwartz CJ, Valente AJ, Sprague EA et al. Atherosclerosis as an inflammatory process. The roles of the monocyte-macrophage. Ann N Y Acad Sci 1985; 454: 115-120. (Pubitemid 16198842)
17. Jonasson L, Holm J, Skalli O et al. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986; 6: 131-138. (Pubitemid 16024121)
18. Stratford N, Britten K, Gallagher P. Inflammatory infiltrates in human coronary atherosclerosis. Atherosclerosis 1986; 59: 271-276. (Pubitemid 16163842)
19. Bylock AL, Gerrity RG. Visualization of monocyte recruitment into atherosclerotic arteries using fluorescent labelling. Atherosclerosis 1988; 71: 17-25.
20. Witztum JL. The role of oxidized LDL in atherosclerosis. Adv Exp Med Biol 1991; 285: 353-365.
21. Schwartz CJ, Kelley JL, Nerem RM et al. Pathophysiology of the atherogenic process. Am J Cardiol 1989; 64: 23G-30G. (Pubitemid 19244570)
22. Frostegard J, Nilsson J, Haegerstrand A et al. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA 1990; 87: 904-908.
23. Cathcart MK, McNally AK, Morel DW et al. Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein and conversion of low-density lipoprotein to a cytotoxin. J Immunol 1989; 142: 1963-1969. (Pubitemid 19081549)
24. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809. (Pubitemid 23132154)
25. Schwartz CJ, Valente AJ, Sprague EA et al. The pathogenesis of atherosclerosis: an overview. Clin Cardiol 1991; 14: I1-16.
26. Faruqi RM, DiCorleto PE. Mechanisms of monocyte recruitment and accumulation. Br Heart J 1993; 69: S19-S29. (Pubitemid 23035603)
27. Dixit VM, Green S, Sarma V et al. Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem 1990; 265: 2973-2978.
28. Uyemura K, Demer LL, Castle SC et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130-2138. (Pubitemid 26143968)
29. Gupta S, Pablo AM, Jiang X et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997; 99: 2752-2761. (Pubitemid 27259823)
30. Cybulsky MI, Gimbrone Jr MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 788-791.
31. Marui N, Offermann MK, Swerlick R et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92: 1866-1874. (Pubitemid 23304554)
32. van der Wal AC, Das PK, Tigges AJ et al. Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am J Pathol 1992; 141: 1427-1433. (Pubitemid 23002626)
33. Gerszten RE, Garcia-Zepeda EA, Lim YC et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398: 718-723.
34. Nageh MF, Sandberg ET, Marotti KR et al. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1997; 17: 1517-1520. (Pubitemid 27387771)
35. Collins RG, Velji R, Guevara NV et al. P-selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2000; 191: 189-194. (Pubitemid 30043660)
36. Hansson GK, Jonasson L, Seifert PS et al. Immune mechanisms in atherosclerosis. Arteriosclerosis 1989; 9: 567-578. (Pubitemid 19236891)
37. Zhou X, Nicoletti A, Elhage R et al. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000; 102: 2919-2922.
38. Song L, Leung C, Schindler C. Lymphocytes are important in early atherosclerosis. J Clin Invest 2001; 108: 251-259. (Pubitemid 32656249)
39. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
40. Wang Z, Liu B, Wang P et al. Phospholipase C beta3 deficiency leads to macrophage hypersensitivity to apoptotic induction and reduction of atherosclerosis in mice. J Clin Invest 2008; 118: 195-204.
41. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001; 104: 503-516.
42. Inoue S, Egashira K, Ni W et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002; 106: 2700-2706. (Pubitemid 35364925)
43. Gordon S. Macrophage heterogeneity and tissue lipids. J Clin Invest 2007; 117: 89-93. (Pubitemid 46048455)
44. Schober A, Zernecke A, Liehn EA et al. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. Circ Res 2004; 95: 1125-1133. (Pubitemid 39557900)
45. Boring L, Gosling J, Cleary M et al. Decreased lesion formation in CCR2f/r mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-897. (Pubitemid 28410911)
46. Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1r/f mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003; 111: 333-340. (Pubitemid 36182209)
47. McDermott DH, Fong AM, Yang Q et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 2003; 111: 1241-1250. (Pubitemid 36519941)
48. Swirski FK, Nahrendorf M, Etzrodt M et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009; 325: 612-616.
49. Aiello RJ, Perry BD, Bourassa PA et al. CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE(L2/C2) mice. Atherosclerosis 2010; 208: 370-375.
50. Sun J, Sukhova GK, Wolters PJ et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 2007; 13: 719-724. (Pubitemid 46889760)
51. Heikkila HM, Trosien J, Metso J et al. Mast cells promote atherosclerosis by inducing both an atherogenic lipid profile and vascular inflammation. J Cell Biochem 2010; 109: 615-623.
52. Kovanen PT. Mast cells: multipotent local effector cells in atherothrombosis. Immunol Rev 2007; 217: 105-122. (Pubitemid 46718148)
53. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010; 11: 197-206.
54. To K, Agrotis A, Besra G et al. NKT cell subsets mediate differential proatherogenic effects in ApoEf/r mice. Arterioscler Thromb Vasc Biol 2009; 29: 671-677.
55. Bobryshev YV, Lord RS. S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc Res 1995; 29: 689-696.
56. Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin Immunol 2010; 134: 25-32.
57. Paulson KE, Zhu SN, Chen M et al. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ Res 2009; 106: 383-390.
58. Swaminathan S, Griffin MD. First responders: understanding monocytelineage traffic in the acutely injured kidney. Kidney Int 2008; 74: 1509-1511.
59. Trogan E, Feig JE, Dogan S et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci USA 2006; 103: 3781-3786. (Pubitemid 43376632)
60. Jonasson L, Holm J, Skalli O et al. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 1985; 76: 125-131. (Pubitemid 15240426)
61. Palinski W, Rosenfeld ME, Yla-Herttuala S et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989; 86: 1372-1376. (Pubitemid 19061548)
62. Stemme S, Faber B, Holm J et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 1995; 92: 3893-3897.
63. Zhou X, Robertson AK, Hjerpe C et al. Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 864-870. (Pubitemid 43732164)
64. Caligiuri G, Nicoletti A, Poirier B et al. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002; 109: 745-753. (Pubitemid 34263151)
65. Binder CJ, Horkko S, Dewan A et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9: 736-743. (Pubitemid 36749223)
66. Nguyen JT, Myers N, Palaia J et al. Humoral responses to oxidized lowdensity lipoprotein and related bacterial antigens after pneumococcal vaccine. Transl Res 2007; 150: 172-179. (Pubitemid 47307448)
67. Binder CJ. Natural IgM antibodies against oxidation-specific epitopes. J Clin Immunol 2010; 30(Suppl 1): S56-S60.
68. Freire de Carvalho J, Sherer Y, Shoenfeld Y. The fine-tuning of antioxidized low-density lipoprotein antibodies in cardiovascular disease and thrombosis. Thromb Haemost 2007; 98: 1157-1159. (Pubitemid 350239084)
69. Ait-Oufella H, Herbin O, Bouaziz JD et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010; 207: 1579-1587.
70. Kyaw T, Tay C, Khan A et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol 2010; 185: 4410-4419.
71. Ait-Oufella H, Salomon BL, Potteaux S et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12: 178-180. (Pubitemid 43214743)
72. Hermansson A, Ketelhuth DF, Strodthoff D et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med 2010; 207: 1081-1093.
73. Klingenberg R, Lebens M, Hermansson A et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 946-952.
74. van der Zee S, Baber U, Elmariah S et al. Cardiovascular risk factors in patients with chronic kidney disease. Nat Rev Cardiol 2009; 6: 580-589.
75. Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 2008; 4: 672-681.
76. Muntner P, He J, Astor BC et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16: 529-538. (Pubitemid 41725151)
77. Fernandez-Fresnedo G, Ramos MA, Gonzalez-Pardo MC et al. B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. Nephrol Dial Transplant 2000; 15: 502-510. (Pubitemid 30160657)
78. Lim WH, Kireta S, Leedham E et al. Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients. Kidney Int 2007; 72: 1138-1148. (Pubitemid 47609031)
79. Agrawal S, Gollapudi P, Elahimehr R et al. Effects of end-stage renal disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine production. Nephrol Dial Transplant 2010; 25: 737-746.
80. Sester U, Sester M, Heine G et al. Strong depletion of CD14(+)CD16(+) monocytes during haemodialysis treatment. Nephrol Dial Transplant 2001; 16: 1402-1408. (Pubitemid 32640595)
81. Girndt M, Sester M, Sester U et al. Molecular aspects of T-and B-cell function in uremia. Kidney Int Suppl 2001; 78: S206-S211. (Pubitemid 32144099)
82. Cohen EP, Russell TJ, Garancis JC. Mast cells and calcium in severe uremic itching. Am J Med Sci 1992; 303: 360-365.
83. Neiman RS, Bischel MD, Lukes RJ. Uraemia and mast-cell proliferation. Lancet 1972; 1: 959.
84. Hu MC, Shi M, Zhang J et al. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int 2010; 78: 1240-1251.
85. Witkowski JM, Soroczynska-Cybula M, Bryl E et al. Klotho-a common link in physiological and rheumatoid arthritis-related aging of human CD4+ lymphocytes. J Immunol 2007; 178: 771-777. (Pubitemid 46095149)
86. Betjes MG, Huisman M, Weimar W et al. Expansion of cytolytic CD4+CD28T cells in end-stage renal disease. Kidney Int 2008; 74: 760-767.
87. Betjes MG, Litjens NH, Zietse R. Seropositivity for cytomegalovirus in patients with end-stage renal disease is strongly associated with atherosclerotic disease. Nephrol Dial Transplant 2007; 22: 3298-3303. (Pubitemid 350202544)
88. Meier P, Golshayan D, Blanc E et al. Oxidized LDL modulates apoptosis of regulatory T cells in patients with ESRD. J Am Soc Nephrol 2009; 20: 1368-1384.
89. Nazarov-Stoica C, Surls J, Bona C et al. CD28 signaling in T regulatory precursors requires p56lck and rafts integrity to stabilize the Foxp3 message. J Immunol 2009; 182: 102-110.
90. Axelsson J. The emerging biology of adipose tissue in chronic kidney disease: from fat to facts. Nephrol Dial Transplant 2008; 23: 3041-3046.
91. Verschuren L, Kooistra T, Bernhagen J et al. MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res 2009; 105: 99-107.
92. Carrero JJ, Hua X, Stenvinkel P et al. Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. Nephrol Dial Transplant 2009; 24: 3454-3460.
93. Wang Z, Nicholls SJ, Rodriguez ER et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007; 13: 1176-1184. (Pubitemid 47530630)
94. Gonen B, Cole T, Hahm KS. The interaction of carbamylated low-density lipoprotein with cultured cells. Studies with human fibroblasts, rat peritoneal macrophages and human monocyte-derived macrophages. Biochim Biophys Acta 1983; 754: 201-207. (Pubitemid 14214001)
95. Kraus LM, Kraus Jr AP. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001; 78: S102-S107. (Pubitemid 32144080)
96. Podrez EA, Schmitt D, Hoff HF et al. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 1999; 103: 1547-1560.
97. Apostolov EO, Ray D, Savenka AV et al. Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol 2010; 21: 1852-1857.
98. Ok E, Basnakian AG, Apostolov EO et al. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int 2005; 68: 173-178. (Pubitemid 43181374)
99. Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001; 12: 1549-1557. (Pubitemid 32666340)
100. Lewis KE, Kirk EA, McDonald TO et al. Increase in serum amyloid as evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation 2004; 110: 540-545. (Pubitemid 39031170)
101. Johnson BD, Kip KE, Marroquin OC et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109: 726-732. (Pubitemid 38222891)
102. Bang CA, Bro S, Bartels ED et al. Effect of uremia on HDL composition, vascular inflammation, and atherosclerosis in wild-type mice. Am J Physiol Renal Physiol 2007; 293: F1325-F1331. (Pubitemid 47583968)
103. Hirano T, Nohtomi K, Nakanishi N et al. Ezetimibe decreases serum amyloid A levels in HDL3 in hemodialysis patients. Clin Nephrol 2010; 74: 282-287.
104. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet 2011; doi:10.1016/S0140-6736(11)60739-3.
105. Ahmed MH. Ezetimibe and recent clinical trials: a look on the bright side. Expert Opin Drug Saf 2010; 9: 511-514.
106. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248. (Pubitemid 41058323)
107. Chait A, Han CY, Oram JF et al. Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005; 46: 389-403.
108. Schiavon R, Battaglia P, De Fanti E et al. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta 2002; 324: 39-44. (Pubitemid 35245493)
109. Quaschning T, Krane V, Metzger T et al. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis 2001; 38: S14-S19. (Pubitemid 32927605)
110. Small DM. George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis 1988; 8: 103-129. (Pubitemid 18090919)
111. Stary HC, Chandler AB, Dinsmore RE et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995; 15: 1512-1531.
112. Nissen SE, Tuzcu EM, Brewer HB et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006; 354: 1253-1263.
113. Duewell P, Kono H, Rayner KJ et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361.
114. Massy ZA, Ivanovski O, Nguyen-Khoa T et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 2005; 16: 109-116. (Pubitemid 43073162)
115. McCullough PA, Agrawal V, Danielewicz E et al. Accelerated atherosclerotic calcification and Monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1585-1598.
116. Xu S, Yu JJ. Beneath the minerals, a layer of round lipid particles was identified to mediate collagen calcification in compact bone formation. Biophys J 2006; 91: 4221-4229. (Pubitemid 44887280)
117. Stenvinkel P, Wang K, Qureshi AR et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005; 67: 2383-2392. (Pubitemid 41623401)
118. Westenfeld R, Schafer C, Kruger T et al. Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol 2009; 20: 1264-1274.
119. Ketteler M, Bongartz P, Westenfeld R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833. (Pubitemid 36331846)
120. Jahnen-Dechent W, Schafer C, Ketteler M et al. Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification. J Mol Med 2008; 86: 379-389.
121. Hornung V, Bauernfeind F, Halle A et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9: 847-856.
122. Shah SV, Alam MG. Role of iron in atherosclerosis. Am J Kidney Dis 2003; 41: S80-S83. (Pubitemid 36278352)
123. Salonen JT, Nyyssonen K, Korpela H et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86: 803-811.
124. Kirk EA, Heinecke JW, LeBoeuf RC. Iron overload diminishes atherosclerosis in apoE-deficient mice. J Clin Invest 2001; 107: 1545-1553. (Pubitemid 32574641)
125. Baliga R, Ueda N, Shah SV. Kidney iron status in passive Heymann nephritis and the effect of an iron-deficient diet. J Am Soc Nephrol 1996; 7: 1183-1188. (Pubitemid 27468271)
126. Baliga R, Ueda N, Shah SV. Increase in bleomycin-detectable iron in ischaemia/reperfusion injury to rat kidneys. Biochem J 1993; 291(Part 3): 901-905. (Pubitemid 23148470)
127. Juan SH, Lee TS, Tseng KW et al. Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 104: 1519-1525.
128. Wang L, Harrington L, Trebicka E et al. Selective modulation of TLR4-activated inflammatory responses by altered iron homeostasis in mice. J Clin Invest 2009; 119: 3322-3328.
129. Wang L, Johnson EE, Shi HN et al. Attenuated inflammatory responses in hemochromatosis reveal a role for iron in the regulation of macrophage cytokine translation. J Immunol 2008; 181: 2723-2731.
130. Ishizaka N, Saito K, Mori I et al. Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin II-infused rats. Arterioscler Thromb Vasc Biol 2005; 25: 2282-2288. (Pubitemid 41552643)
131. Zager RA. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. Kidney Int 2005; 68: 1533-1542. (Pubitemid 43173381)
132. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 2006; 1(Suppl 1): S19-S23.
133. Schaller G, Scheiber-Mojdehkar B, Wolzt M et al. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Kidney Int 2005; 68: 2814-2822. (Pubitemid 43251028)
134. Shah SV, Baliga R, Rajapurkar M et al. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007; 18: 16-28. (Pubitemid 46053418)
135. Solomon SD, Uno H, Lewis EF et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363: 1146-1155.
136. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
137. Robach P, Recalcati S, Girelli D et al. Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. Blood 2009; 113: 6707-6715.
138. Nagy E, Eaton JW, Jeney V et al. Red cells, hemoglobin, heme, iron, and atherogenesis. Arterioscler Thromb Vasc Biol 2010; 30: 1347-1353.
139. Kolodgie FD, Gold HK, Burke AP et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316-2325. (Pubitemid 37509739)
140. Means Jr RT. Neocytolysis: from outer space to the dialysis unit. Am J Kidney Dis 1999; 33: 140-141.
141. Kaufman JS. Subcutaneous erythropoietin therapy: efficacy and economic implications. Am J Kidney Dis 1998; 32: S147-S151.
142. Moreno PR, Purushothaman KR, Purushothaman M et al. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. J Am Coll Cardiol 2008; 52: 1049-1051.
143. Levy AP, Levy JE, Kalet-Litman S et al. Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2007; 27: 134-140. (Pubitemid 46360390)
144. Burbea Z, Nakhoul F, Rosenberg S et al. Role of haptoglobin phenotype in end-stage kidney disease. Nephron Exp Nephrol 2004; 97: e71-e76.
145. Singh RN. Progression of coronary atherosclerosis. Clues to pathogenesis from serial coronary arteriography. Br Heart J 1984; 52: 451-461. (Pubitemid 14002049)
146. Ishani A, Xue JL, Himmelfarb J et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009; 20: 223-228.
147. Kelly KJ, Dominguez JH. Rapid progression of diabetic nephropathy is linked to inflammation and episodes of acute renal failure. Am J Nephrol 2010; 32: 469-475.
148. Singh P, Rifkin DE, Blantz RC. Chronic kidney disease: an inherent risk factor for acute kidney injury? Clin J Am Soc Nephrol 2010; 5: 1690-1695.
149. Okusa MD, Chertow GM, Portilla D. The nexus of acute kidney injury, chronic kidney disease, and World Kidney Day 2009. Clin J Am Soc Nephrol 2009; 4: 520-522.
150. Rihal CS, Textor SC, Grill DE et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264. (Pubitemid 34535335)
151. Parikh CR, Coca SG, Wang Y et al. Long-term prognosis of acute kidney injury after acute myocardial infarction. Arch Intern Med 2008; 168: 987-995. (Pubitemid 351679639)
152. Grigoryev DN, Liu M, Hassoun HT et al. The local and systemic inflammatory transcriptome after acute kidney injury. J Am Soc Nephrol 2008; 19: 547-558. (Pubitemid 351355398)
153. Dong X, Swaminathan S, Bachman LA et al. Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int 2007; 71: 619-628. (Pubitemid 46494569)
154. Yang L, Besschetnova TY, Brooks CR et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010; 16: 535-543, 531p following 143.
155. Bonventre JV. Pathophysiology of AKI: injury and normal and abnormal repair. Contrib Nephrol 2010; 165: 9-17.
156. Burne-Taney MJ, Yokota N, Rabb H. Persistent renal and extrarenal immune changes after severe ischemic injury. Kidney Int 2005; 67: 1002-1009. (Pubitemid 41623323)
157. Murray PT. The kidney in respiratory failure and mechanical ventilation. Contrib Nephrol 2010; 165: 159-165.
158. Li X, Hassoun HT, Santora R et al. Organ crosstalk: the role of the kidney. Curr Opin Crit Care 2009; 15: 481-487.
159. Van Laethem C, Bartunek J, Goethals M et al. Chronic kidney disease is associated with decreased exercise capacity and impaired ventilatory efficiency in heart transplantation patients. J Heart Lung Transplant 2009; 28: 446-452.
160. Yoon SH, Choi NW, Yun SR. Pulmonary dysfunction is possibly a marker of malnutrition and inflammation but not mortality in patients with endstage renal disease. Nephron Clin Pract 2009; 111: c1-c6.
161. Nascimento MM, Qureshi AR, Stenvinkel P et al. Malnutrition and inflammation are associated with impaired pulmonary function in patients with chronic kidney disease. Nephrol Dial Transplant 2004; 19: 1823-1828. (Pubitemid 38961394)
162. Hancox RJ, Poulton R, Greene JM et al. Systemic inflammation and lung function in young adults. Thorax 2007; 62: 1064-1068. (Pubitemid 350206198)
163. Jang HR, Gandolfo MT, Ko GJ et al. B cells limit repair after ischemic acute kidney injury. J Am Soc Nephrol 2010; 21: 654-665.
164. Segerer S, Schlondorff D. B cells and tertiary lymphoid organs in renal inflammation. Kidney Int 2008; 73: 533-537. (Pubitemid 351264112)
165. Steinmetz OM, Stahl RA, Panzer U. Formation of lymphoid-like tissue in the kidney-is there a role for chemokines? Nephrol Dial Transplant 2007; 22: 350-352. (Pubitemid 46189876)
166. Welsh-Bacic D, Lindenmeyer M, Cohen CD et al. Expression of the chemokine receptor CCR6 in human renal inflammation. Nephrol Dial Transplant 2010; 26: 1211-1220.
167. Drayton DL, Liao S, Mounzer RH et al. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006; 7: 344-353.